Login to Your Account



Agenus Is Hit Hard by GSK Trial Failure

By Catherine Shaffer
Staff Writer

Friday, September 6, 2013
Shares of Agenus Inc., of Lexington, Mass., plummeted 23.5 percent on news that Glaxosmithkline plc’s Phase III DERMA trial testing its MAGE-A3 cancer immunotherapeutic, formulated with Agenus’s QS-21 Stimulon adjuvant, missed its primary endpoint. The trial failed to significantly extend disease-free survival in melanoma patients compared to placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription